Skip to content
Checked.be
Complete company report
Generated 04-09-2026
Active BE 1014.612.476Private limited company

MDL studies

Deltalaan 1 ·8800 Roeselare, Belgium· 1 yrs active
Sector: Medical imaging and medical laboratories (86910)
Conclusion Checked

MDL studies has been active since 2024 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €418k and a net result of €250k. Its solvency ranks better than 65% of 2224 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).

Based on the State Gazette, CBE and 2 annual accounts.
Key figures
Equity €418k
Net result €250k
Better than sector 65%
Active 1 yrs
Financial profile 5 of 5 axes measured · computed by Checked
Health93Profitability100Solvency100Growth78Stability82
91 / 100

Exceptional profile, strong across almost every axis.

All 5 axes are computed from data Checked has read.

Health 93
Profitability 100
Solvency 100
Growth 78
Stability 82
Bankruptcy probability (12 mo) Checked model v1 · free
0.1% Very low
0%0,5%1,5%4%10%≥25%

How do we compute this?

Risk Assessment rule-based
0 / 100
Low risk
Trust signals 2 signals
Young company
Founded in 2024, under 3 years, statistically higher risk.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.
Administrative Flags0 events
No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
Checked score FY 2025 · computed
93 / 100 Excellent
050100
Computed from 4 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.
Indicative credit limit
€40k
estimate, not credit advice
Score history
78 2024
93 2025
purely financial, excl. current insolvency signals
Score components
Liquidity Current ratio 4.02 (≥ 1.5) +10
Quick ratio Quick ratio 4.02 (≥ 1.0) +5
Leverage Debt/equity 0.33 (< 1.0) +10
Profitability ROE 60% (≥ 10%) +10
Profit trend Net profit up YoY +5
Equity growth Equity growing YoY +3
Computed by Checked from the NBB filing for FY 2025. Indicative, not credit advice.
Financial overview2 NBB filings
Annual accounts filed on 10-07-2026 with the NBB · fiscal year 2025 · micro schema
€0€100k€200k€300kOperating result 2024: €210k€210kNet result 2024: €162k€162kOperating result 2025: €329k€329kNet result 2025: €250k€250k20242025
Operating resultNet result
Sector comparison
Fiscal year 2025 · NACE 86, Human health activities · compared within the same schema type (micro schema)
Metric This company Sector median Position in the sector
Solvency 75.1% 57.9%
better than 65% of 2224 sector peers
Net result €250k €59k
better than 94% of 2222 sector peers
Equity €418k €74k
better than 93% of 2224 sector peers
Gross operating margin €348k €95k
better than 93% of 2224 sector peers
Staff costs €19k €22k
higher than 47% of 362 sector peers
Net profit
€250k
+54.3% 24-25
Total assets
€556k
+56.0% 24-25
Equity
€418k
+149.5% 24-25
Working capital
€418k
+149.5% 24-25
Staff costs
€19k
- 24-25
Income taxes
€79k
+65.8% 24-25
Debt
€138k
-26.9% 24-25
Debt ≤ 1y
€138k
-26.9% 24-25
Current ratio
4.02
+113.3% 24-25
Quick ratio
4.02
+113.3% 24-25
Solvency
75.1%
+59.9% 24-25
Debt / equity
0.33
-70.7% 24-25
ROE
59.9%
-38.1% 24-25
ROA
45.0%
-1.1% 24-25
Figures by fiscal year and ratios
Fiscal year20252024
Depositmicro schemamicro schema
Revenue--
EBITDA--
Net profit€250k€162k
Cash flow--
Staff costs€19k-
Income taxes€79k€47k
Dividends--
Total assets€556k€356k
Equity€418k€167k
Debt€138k€189k
of which ≤ 1y€138k€189k
of which > 1y--
Working capital€418k€167k
Employees (FTE)--
Ratios (computed)
20252024
Current ratio4.021.89
Quick ratio4.021.89
Working capital ratio75.1%47.0%
Solvency75.1%47.0%
Debt / equity0.331.13
Long-term debt ratio--
Interest coverage--
Gross margin--
Net margin--
ROA45.0%45.5%
ROE59.9%96.9%
EBITDA margin--
Days sales outstanding--
Days payable outstanding--
Inventory turnover--
Days inventory (DSI)--
Balance-sheet composition 2025
Full annual accounts (18 line items)
Filed balance sheet and income statement, exactly as deposited with the NBB.
Line item Code20252024
Balance sheet, Assets
TOTAL ASSETS 20/58€556k€356k
Current assets 29/58€556k€356k
Amounts receivable within one year 40/41€231k€201k
Cash & bank 54/58€324k€155k
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES 10/49€556k€356k
Equity 10/15€418k€167k
Contributions / capital 10/11€5k€5k
Reserves 13€412k€162k
Amounts payable 17/49€138k€189k
Amounts payable within one year 42/48€138k€189k
Trade debts payable within one year 44€57k€128k
Income statement
Gross operating margin 9900€348k€210k
Operating result 9901€329k€210k
Financial charges 65€63€3
Result before taxes 9903€329k€210k
Income taxes 67/77€79k€47k
Net result for the period 9904€250k€162k
Result to be appropriated 9905€250k€162k
Legal Structure
NACE primary Medical imaging and medical laboratories(86910)
Legal form Private limited company(610)
Incorporation03-10-2024
StatusActive
Postal code8800
Establishment units 1 location
MDL studies
Deltalaan 1, 8800 RoeselareOrganisation of conventions and trade shows
since 20242.364.799.424
Real-estate footprint Source: CBE × cadastre
Flanders 1 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
36017A1048/00B000 Flanders 16.7 ha 1 · 2.4 ha -
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Updates 2 events
Next filing, fiscal year 2026, expected by 31-07-2027
2026
10-07
NBB filing Annual accounts filed
fiscal year 2025 · micro schema
2025
31-12
Financial Liquidity doublescurrent ratio 4.02
Current ratio from 1.89 to 4.02; short-term debt falls from €189k to €138k.
31-12
Financial Equity above €200kEq €418k ▲150%
2 profitable years in a row build equity to €418k.
17-07
NBB filing Annual accounts filed
fiscal year 2024 · micro schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Belgian State Gazette reading coverage 0 of 1 acts read

We know of 1 Belgian State Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.

Credit advice verdict per customer and amount
Company registry (CBE) Crossroads Bank
Activities
Human health activities86901Medical imaging and medical laboratories86910Organisation of conventions and trade shows82300Other business support services82990Other education85599Human health activities86909Nutrition and dietetics services86995
Names & trade names
Legal nameNL MDL studies
Similar companies Comparable size · 514 of 700 companies in this sector with filed accounts
AMAKEM BE 0817.285.772 · Hasselt
Dorien Van den Bossche BE 0773.791.764 · Keerbergen
DOKTER LODE VERMEERSCH, ALGEMENE GENEESKUNDE BE 0879.471.779 · Tremelo
LABORATOIRE DE L'INSTITUT MEDICAL SPECIALISE BE 0424.567.020 · Ottignies-Louvain-la-Neuve
Minrad BE 0460.073.968 · Gesves
Source: Belgian State Gazette, CBE, NBB · generated via checked.be · indicative